W

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Business Management
Share
Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Source：MarketWatch

Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.

Related Reading

Bitcoin’s BIP-110 enters mandatory signaling with miner support below 3%

The deployment milestone tests whether enforcing nodes can sustain the change amid limited miner signaling and discussion of a hardfork fallback.…

Bitcoin hits block 961,632 as the controversial BIP-110 soft fork attempt begins

The proposal has scant support from bitcoin miners and influential commentators have also voiced their opposition. Source：CoinDesk

Hardware wallet sales in Russia more than double as new crypto rules near

Wildberries’ average price for hardware wallets fell 13% to 7,900 rubles, and M.Video broadened its range of products, though neither retailer identified the…

US spot Bitcoin ETFs post best week since April with $1B inflows

The spot Bitcoin exchangetraded funds registered their thirdstrongest showing since October as institutional demand showed signs of renewed momentum.…

Source：https://www.marketwatch.com/story/lillys-revenue-soars-48-driven-by-demand-of-its-glp-1s-7361c223